Effect of Ezetimibe on visceral fat suppression in patients with chronic liver disease and hyperlipidemia ; a randomized, double blind, placebo-controlled, clinical trial.

Trial Profile

Effect of Ezetimibe on visceral fat suppression in patients with chronic liver disease and hyperlipidemia ; a randomized, double blind, placebo-controlled, clinical trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2012

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2012 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 07 May 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 03 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top